AUS
NZ
UK
CA
USA
IND
Highlights:
- Humacyte (NASDAQ:HUMA) shares rose by 11.2%.
- The company’s market capitalization is $576.43 million.
- Key financial metrics include a quick ratio of 1.10, a current ratio of 1.10, and a debt-to-equity ratio of 0.61.
Humacyte is part of the biotechnology sector, with a focus on developing human tissue-based products aimed at treating serious medical conditions. The company utilizes tissue engineering techniques to create biologically derived products that can be applied across a range of therapeutic areas.
Key Financial Metrics
Humacyte’s stock opened at $4.58, reflecting an increase of 11.2%. The company has a quick ratio and current ratio both of 1.10, demonstrating its capacity to meet short-term liabilities with liquid assets. The debt-to-equity ratio stands at 0.61, indicating a relatively moderate level of debt compared to equity. These ratios provide insight into the company’s operational efficiency and its management of financial responsibilities.
Stock Performance and Historical Data
Over the past year, Humacyte's stock has ranged between a low of $2.48 and a high of $9.97. Currently, the fifty-day simple moving average is $4.62, closely matching the opening stock price, while the 200-day simple moving average is $5.67. This suggests the stock has experienced fluctuations, with a downward trend observed over the longer term.
Market Capitalization and Risk Indicators
With a market capitalization of $576.43 million, Humacyte ranks as a smaller player in the biotech industry. The company has a beta of 1.32, reflecting increased volatility compared to the broader market. This elevated beta signals greater risk, particularly during periods of market fluctuation.
Debt and Liquidity Management
Humacyte maintains a debt-to-equity ratio of 0.61, indicating that the company uses moderate leverage in its operations. This ratio suggests a higher proportion of equity compared to debt, which is often seen as a sign of financial stability in terms of managing both operational costs and expansion activities.
Humacyte’s financial figures provide a detailed snapshot of its position within the biotechnology sector. The company's stock performance, market capitalization, and financial ratios reflect various aspects of its current standing in a competitive and rapidly evolving field.
